JP2022500402A5 - - Google Patents
Info
- Publication number
- JP2022500402A5 JP2022500402A5 JP2021513827A JP2021513827A JP2022500402A5 JP 2022500402 A5 JP2022500402 A5 JP 2022500402A5 JP 2021513827 A JP2021513827 A JP 2021513827A JP 2021513827 A JP2021513827 A JP 2021513827A JP 2022500402 A5 JP2022500402 A5 JP 2022500402A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- pyrimidine
- methyl
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024096058A JP2024123079A (ja) | 2018-09-12 | 2024-06-13 | トリアゾロ－ピリミジン化合物およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105220 | 2018-09-12 | ||
| CNPCT/CN2018/105220 | 2018-09-12 | ||
| PCT/CN2019/105591 WO2020052631A1 (en) | 2018-09-12 | 2019-09-12 | Triazolo-pyrimidine compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024096058A Division JP2024123079A (ja) | 2018-09-12 | 2024-06-13 | トリアゾロ－ピリミジン化合物およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500402A JP2022500402A (ja) | 2022-01-04 |
| JP2022500402A5 true JP2022500402A5 (enExample) | 2022-09-05 |
| JP7572353B2 JP7572353B2 (ja) | 2024-10-23 |
Family
ID=69778192
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513827A Active JP7572353B2 (ja) | 2018-09-12 | 2019-09-12 | トリアゾロ－ピリミジン化合物およびそれらの使用 |
| JP2024096058A Pending JP2024123079A (ja) | 2018-09-12 | 2024-06-13 | トリアゾロ－ピリミジン化合物およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024096058A Pending JP2024123079A (ja) | 2018-09-12 | 2024-06-13 | トリアゾロ－ピリミジン化合物およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10858365B2 (enExample) |
| EP (1) | EP3849983A4 (enExample) |
| JP (2) | JP7572353B2 (enExample) |
| KR (1) | KR102841843B1 (enExample) |
| CN (3) | CN111601809A (enExample) |
| AR (1) | AR116315A1 (enExample) |
| AU (1) | AU2019340767B9 (enExample) |
| BR (1) | BR112021004774A2 (enExample) |
| CA (1) | CA3111869A1 (enExample) |
| MX (1) | MX2021002998A (enExample) |
| TW (1) | TWI820209B (enExample) |
| WO (1) | WO2020052631A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600328A4 (en) * | 2017-03-24 | 2021-01-06 | 3100 Central Expressway LLC | MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION |
| JP2020527588A (ja) | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| AU2019227607C1 (en) * | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| PH12022550470A1 (en) * | 2019-08-26 | 2023-02-27 | Incyte Corp | Triazolopyrimidines as a2a / a2b inhibitors |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
| CN120022278A (zh) * | 2023-11-22 | 2025-05-23 | 英诺湖医药(杭州)有限公司 | 用于治疗癌症的化合物 |
| CN117865963B (zh) * | 2023-12-15 | 2026-02-24 | 上海凌凯科技股份有限公司 | 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042711A1 (en) * | 1997-03-24 | 1998-10-01 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
| WO2002079204A1 (en) | 2001-03-28 | 2002-10-10 | Kyowa Hakko Kogyo Co., Ltd. | 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative |
| TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| AU2003272886A1 (en) | 2002-09-24 | 2004-04-19 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE |
| MX389798B (es) * | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| KR20190129851A (ko) * | 2017-03-16 | 2019-11-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도 |
| EP3611174B1 (en) * | 2017-04-07 | 2022-06-08 | Medshine Discovery Inc. | [1,2,4]triazolo[1,5-c]pyrimidine derivative as a2a receptor inhibitor |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| AU2019227607C1 (en) * | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| CN112105617B (zh) * | 2018-04-28 | 2022-04-05 | 南京明德新药研发有限公司 | 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
-
2019
- 2019-09-11 AR ARP190102589A patent/AR116315A1/es unknown
- 2019-09-11 TW TW108132759A patent/TWI820209B/zh active
- 2019-09-12 CN CN201980006436.2A patent/CN111601809A/zh active Pending
- 2019-09-12 JP JP2021513827A patent/JP7572353B2/ja active Active
- 2019-09-12 WO PCT/CN2019/105591 patent/WO2020052631A1/en not_active Ceased
- 2019-09-12 MX MX2021002998A patent/MX2021002998A/es unknown
- 2019-09-12 BR BR112021004774-3A patent/BR112021004774A2/pt unknown
- 2019-09-12 KR KR1020217010809A patent/KR102841843B1/ko active Active
- 2019-09-12 CA CA3111869A patent/CA3111869A1/en active Pending
- 2019-09-12 EP EP19859380.8A patent/EP3849983A4/en active Pending
- 2019-09-12 AU AU2019340767A patent/AU2019340767B9/en active Active
- 2019-09-12 CN CN202010657655.1A patent/CN112279852B/zh active Active
- 2019-09-12 CN CN202010656938.4A patent/CN111635408B/zh active Active
-
2020
- 2020-06-24 US US16/910,334 patent/US10858365B2/en active Active
- 2020-09-22 US US17/027,740 patent/US11629147B2/en active Active
-
2024
- 2024-06-13 JP JP2024096058A patent/JP2024123079A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247027B2 (en) | P2X7 modulators | |
| US20220241261A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| JP2016529292A5 (enExample) | ||
| JP2021533179A5 (enExample) | ||
| JP2016537384A5 (enExample) | ||
| KR102841843B1 (ko) | 트리아졸로-피리미딘 화합물 및 그의 용도 | |
| JP2012515205A5 (enExample) | ||
| JP2025535046A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質の複素環阻害剤及びその使用 | |
| JP2012532931A5 (enExample) | ||
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| JP2016500671A5 (enExample) | ||
| JP2019504821A5 (enExample) | ||
| US20130310340A1 (en) | Method of treating muscular degradation | |
| JP2016504290A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| JP2016522246A5 (enExample) | ||
| JP2019535664A5 (enExample) | ||
| JP2017520607A5 (enExample) | ||
| JP2013508404A5 (enExample) | ||
| EP2920177A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP2016522232A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| JP2022534302A5 (enExample) | ||
| JP2020502230A5 (enExample) |